» Articles » PMID: 27536319

Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations

Overview
Journal Front Genet
Date 2016 Aug 19
PMID 27536319
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

In a variety of solid cancers, missense mutations in the well-established TP53 tumor suppressor gene may lead to the presence of a partially-functioning protein molecule, whereas mutations affecting the protein encoding reading frame, often referred to as null mutations, result in the absence of p53 protein. Both types of mutations have been observed in the same cancer type. As the resulting tumor biology may be quite different between these two groups, we used RNA-sequencing data from The Cancer Genome Atlas (TCGA) from four different cancers with poor prognosis, namely ovarian, breast, lung and skin cancers, to compare the patterns of coexpression of genes in tumors grouped according to their TP53 missense or null mutation status. We used Weighted Gene Coexpression Network analysis (WGCNA) and a new test statistic built on differences between groups in the measures of gene connectivity. For each cancer, our analysis identified a set of genes showing differential coexpression patterns between the TP53 missense- and null mutation-carrying groups that was robust to the choice of the tuning parameter in WGCNA. After comparing these sets of genes across the four cancers, one gene (KIR3DL2) consistently showed differential coexpression patterns between the null and missense groups. KIR3DL2 is known to play an important role in regulating the immune response, which is consistent with our observation that this gene's strongly-correlated partners implicated many immune-related pathways. Examining mutation-type-related changes in correlations between sets of genes may provide new insight into tumor biology.

Citing Articles

Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer.

Eustace A, Lee M, Colley G, Roban J, Downing T, Buchanan P Cancer Drug Resist. 2022; 5(3):560-576.

PMID: 36176752 PMC: 9511797. DOI: 10.20517/cdr.2022.41.


Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer.

Deacu M, Tuta L, Bosoteanu M, Aschie M, Mitroi A, Nicolau A Rom J Morphol Embryol. 2021; 62(1):63-71.

PMID: 34609409 PMC: 8597365. DOI: 10.47162/RJME.62.1.06.


Expression profile analysis to predict potential biomarkers for glaucoma: BMP1, DMD and GEM.

Zhang D, Zhang S, Wu J PeerJ. 2020; 8:e9462.

PMID: 32953253 PMC: 7474882. DOI: 10.7717/peerj.9462.


Meta-Analysis Based on Nonconvex Regularization.

Zhang H, Li S, Zhang H, Yang Z, Ren Y, Xia L Sci Rep. 2020; 10(1):5755.

PMID: 32238826 PMC: 7113298. DOI: 10.1038/s41598-020-62473-2.


A Six-Gene Signature Predicts Survival of Adenocarcinoma Type of Non-Small-Cell Lung Cancer Patients: A Comprehensive Study Based on Integrated Analysis and Weighted Gene Coexpression Network.

Xie H, Xie C Biomed Res Int. 2019; 2019:4250613.

PMID: 31886214 PMC: 6925693. DOI: 10.1155/2019/4250613.


References
1.
Menendez D, Shatz M, Resnick M . Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol. 2012; 25(1):85-92. DOI: 10.1097/CCO.0b013e32835b6386. View

2.
Konecny G, Wang C, Hamidi H, Winterhoff B, Kalli K, Dering J . Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014; 106(10). PMC: 4271115. DOI: 10.1093/jnci/dju249. View

3.
Sfakianos G, Iversen E, Whitaker R, Akushevich L, Schildkraut J, Murphy S . Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol. 2013; 129(1):159-64. PMC: 3733243. DOI: 10.1016/j.ygyno.2012.12.030. View

4.
Liang P, Pardee A . Analysing differential gene expression in cancer. Nat Rev Cancer. 2003; 3(11):869-76. DOI: 10.1038/nrc1214. View

5.
Ravasz E, Somera A, Mongru D, Oltvai Z, Barabasi A . Hierarchical organization of modularity in metabolic networks. Science. 2002; 297(5586):1551-5. DOI: 10.1126/science.1073374. View